CN108570104A - 重组脂联素抗原、抗体及脂联素纳米胶乳增强免疫比浊法试剂盒 - Google Patents
重组脂联素抗原、抗体及脂联素纳米胶乳增强免疫比浊法试剂盒 Download PDFInfo
- Publication number
- CN108570104A CN108570104A CN201810211206.7A CN201810211206A CN108570104A CN 108570104 A CN108570104 A CN 108570104A CN 201810211206 A CN201810211206 A CN 201810211206A CN 108570104 A CN108570104 A CN 108570104A
- Authority
- CN
- China
- Prior art keywords
- adiponectin
- antibody
- antigen
- latex particle
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000011690 Adiponectin Human genes 0.000 title claims abstract description 171
- 108010076365 Adiponectin Proteins 0.000 title claims abstract description 171
- 229920000126 latex Polymers 0.000 title claims abstract description 59
- 239000000427 antigen Substances 0.000 title claims abstract description 39
- 102000036639 antigens Human genes 0.000 title claims abstract description 39
- 108091007433 antigens Proteins 0.000 title claims abstract description 39
- 239000004816 latex Substances 0.000 claims abstract description 49
- 239000002245 particle Substances 0.000 claims abstract description 48
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 45
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 230000014509 gene expression Effects 0.000 claims abstract description 30
- 230000006798 recombination Effects 0.000 claims abstract description 25
- 238000005215 recombination Methods 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 21
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims abstract description 20
- 208000001280 Prediabetic State Diseases 0.000 claims abstract description 20
- 210000002966 serum Anatomy 0.000 claims abstract description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 12
- 239000001963 growth medium Substances 0.000 claims abstract description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 6
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims abstract description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 5
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 5
- 239000012679 serum free medium Substances 0.000 claims abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000007993 MOPS buffer Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000004005 microsphere Substances 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 238000011587 new zealand white rabbit Methods 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 238000005868 electrolysis reaction Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000003014 reinforcing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 5
- 239000008103 glucose Substances 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 15
- 239000000178 monomer Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000011056 performance test Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000005829 trimerization reaction Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010056997 Impaired fasting glucose Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- ZGABFIHCVASNKH-UHFFFAOYSA-N [K].N=C=O Chemical compound [K].N=C=O ZGABFIHCVASNKH-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057799 human ADIPOQ Human genes 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002621 immunoprecipitating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810211206.7A CN108570104B (zh) | 2018-03-14 | 2018-03-14 | 重组脂联素抗原、抗体及脂联素纳米胶乳增强免疫比浊法试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810211206.7A CN108570104B (zh) | 2018-03-14 | 2018-03-14 | 重组脂联素抗原、抗体及脂联素纳米胶乳增强免疫比浊法试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108570104A true CN108570104A (zh) | 2018-09-25 |
CN108570104B CN108570104B (zh) | 2021-11-12 |
Family
ID=63574487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810211206.7A Active CN108570104B (zh) | 2018-03-14 | 2018-03-14 | 重组脂联素抗原、抗体及脂联素纳米胶乳增强免疫比浊法试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108570104B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110372783A (zh) * | 2019-04-15 | 2019-10-25 | 杭州博谱医药科技有限公司 | 一种脂联素抗原、抗体及其胶乳试剂的制备方法以及脂联素检测试剂盒 |
CN111337692A (zh) * | 2020-03-25 | 2020-06-26 | 江西乐成生物医疗有限公司 | 一种脂联素测定试剂及制备方法 |
CN113267635A (zh) * | 2021-04-29 | 2021-08-17 | 广东优尼德生物科技有限公司 | 一种脂联素抗体纳米胶乳颗粒及用于检测脂联素的试剂盒 |
CN117327177A (zh) * | 2022-06-24 | 2024-01-02 | 东莞市朋志生物科技有限公司 | 抗脂联素抗体、检测脂联素的试剂和试剂盒 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN202066863U (zh) * | 2010-10-29 | 2011-12-07 | 厦门大学附属中山医院 | 检测脂联素的颗粒增强免疫透射比浊试剂盒 |
CN103777023A (zh) * | 2013-12-16 | 2014-05-07 | 深圳市安之酶生物技术有限公司 | 纳米胶乳增强免疫比浊法测定脂联素的试剂盒 |
-
2018
- 2018-03-14 CN CN201810211206.7A patent/CN108570104B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN202066863U (zh) * | 2010-10-29 | 2011-12-07 | 厦门大学附属中山医院 | 检测脂联素的颗粒增强免疫透射比浊试剂盒 |
CN103777023A (zh) * | 2013-12-16 | 2014-05-07 | 深圳市安之酶生物技术有限公司 | 纳米胶乳增强免疫比浊法测定脂联素的试剂盒 |
Non-Patent Citations (1)
Title |
---|
MANDAL P等: "Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin", 《JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110372783A (zh) * | 2019-04-15 | 2019-10-25 | 杭州博谱医药科技有限公司 | 一种脂联素抗原、抗体及其胶乳试剂的制备方法以及脂联素检测试剂盒 |
CN111337692A (zh) * | 2020-03-25 | 2020-06-26 | 江西乐成生物医疗有限公司 | 一种脂联素测定试剂及制备方法 |
CN111337692B (zh) * | 2020-03-25 | 2023-10-03 | 江西乐成生物医疗有限公司 | 一种脂联素测定试剂及制备方法 |
CN113267635A (zh) * | 2021-04-29 | 2021-08-17 | 广东优尼德生物科技有限公司 | 一种脂联素抗体纳米胶乳颗粒及用于检测脂联素的试剂盒 |
CN113267635B (zh) * | 2021-04-29 | 2022-02-11 | 广东优尼德生物科技有限公司 | 一种脂联素抗体纳米胶乳颗粒及用于检测脂联素的试剂盒 |
CN117327177A (zh) * | 2022-06-24 | 2024-01-02 | 东莞市朋志生物科技有限公司 | 抗脂联素抗体、检测脂联素的试剂和试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN108570104B (zh) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101454670B (zh) | 测量人巨蛋白的方法 | |
CN109596843B (zh) | 一种血清淀粉样蛋白a的测定试剂盒 | |
CN103852584B (zh) | 一种定量检测c肽的胶乳增强免疫比浊试剂盒 | |
EP2357475B1 (en) | Method for measuring cystatin c in human body fluid | |
CN108152512A (zh) | 肝素结合蛋白检测试剂盒及其制备方法 | |
CN111239421A (zh) | 一种定量检测脂联素adpn的胶乳增强免疫比浊试剂盒及其制备与应用方法 | |
CN102421799B (zh) | 用于高分子脂联素分析的新型单克隆抗体及其应用 | |
CN101833009A (zh) | 一种双抗体复合的视黄醇结合蛋白检测试剂盒 | |
CN108570104A (zh) | 重组脂联素抗原、抗体及脂联素纳米胶乳增强免疫比浊法试剂盒 | |
CN109765382A (zh) | 一种心肌肌钙蛋白t的胶乳增强免疫比浊检测试剂盒 | |
CN104694478B (zh) | 抗人脂联素的单克隆抗体及其应用 | |
CN101581726A (zh) | 新一代布鲁氏菌病抗体竞争酶联免疫吸附试验检测试剂盒 | |
CN101592660B (zh) | 布鲁氏菌病间接酶联免疫吸附试验奶液抗体检测试剂盒 | |
US7659125B2 (en) | Latex reagent for adiponectin analysis and method of adiponectin analysis | |
CN105988001A (zh) | 一种测定非对称二甲基精氨酸浓度的试剂盒及方法 | |
EP1169647B1 (en) | Method for analyzing the amount of intraabdominal adipose tissue | |
CN110133270A (zh) | 一种增强免疫抑制比浊抗体筛选试剂及其制作和使用方法 | |
CN104558112A (zh) | 糖基化多肽及其与载体蛋白的偶联物及其制备方法与应用 | |
CN108918888A (zh) | 一种检测内皮抑素的胶乳增强免疫比浊试剂盒及其应用 | |
CN109580931A (zh) | 一种α1-微球蛋白检测试剂盒 | |
KR101342755B1 (ko) | 미성숙 항체, 이를 이용한 연속 검출장치 및 실시간 연속 검출 방법 | |
CN102721819B (zh) | 一种脂联素的竞争抑制性酶联免疫检测试剂盒及方法 | |
CN111458522A (zh) | 一种用于检测血浆白细胞介素6天然抗体的检测试剂、试剂盒及其应用 | |
CN109900901A (zh) | 改进的诊断真菌感染的方法 | |
CN108226529A (zh) | 一种基于双分子荧光互补技术的NT-proBNP检测试剂盒、制备及使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230911 Address after: Room 201, Building 3, No. 1 Taoyuan Road, Songshan Lake Park, Dongguan City, Guangdong Province, 523000 Patentee after: GUANGDONG UNITEN BIOTECHNOLOGY CO.,LTD. Address before: 523808 Room 408, floor 4, building 3, Guantai biotechnology cooperative breeding center, Taoyuan 1, Songshanhu high tech Zone, Dongguan City, Guangdong Province Patentee before: GUANGDONG YINGNUO BIOTECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231019 Address after: 603-03, Building 1, Meinian ISQUARE, Xingong Road, Taohuayuan Community, Zhaoshang Street, Nanshan District, Shenzhen, Guangdong 518000 Patentee after: Inno Biotechnology (Shenzhen) Co.,Ltd. Address before: Room 201, Building 3, No. 1 Taoyuan Road, Songshan Lake Park, Dongguan City, Guangdong Province, 523000 Patentee before: GUANGDONG UNITEN BIOTECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right |